Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer

Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies

(2019) Mark Kriegsmann et al.   BMC CANCER

A retrospective cohort study of anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer.

(2019) Danyang Sun et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy

(2018) Azfar Neyaz et al.   HISTOPATHOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)

(2018) Hendrik‐Tobias Arkenau et al.   ONCOLOGIST

Characterisation of the immune-related transcriptome in resected biliary tract cancers

(2017) Michele Ghidini et al.   EUROPEAN JOURNAL OF CANCER

Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma

(2017) Glen J. Weiss et al.   INVESTIGATIONAL NEW DRUGS

Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells

(2017) Zibing Wang et al.   OncoImmunology

Mismatch repair protein loss and microsatellite instability in cholangiocarcinoma.

(2017) Lipika Goyal et al.   JOURNAL OF CLINICAL ONCOLOGY

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy

(2015) Xiangjiao Meng et al.   CANCER TREATMENT REVIEWS

525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028

(2015) Y.J. Bang et al.   EUROPEAN JOURNAL OF CANCER

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

(2014) David Malka et al.   LANCET ONCOLOGY

Effects of conventional therapeutic interventions on the number and function of regulatory T cells

(2013) Mario Roselli et al.   OncoImmunology

Cancer and Inflammation: An Old Intuition with Rapidly Evolving New Concepts

(2012) Giorgio Trinchieri   Annual Review of Immunology

Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

(2012) Alice P. Chen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Risk factors for cholangiocarcinoma

(2011) Gia L. Tyson et al.   HEPATOLOGY

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

(2011) W. Joost Lesterhuis et al.   JOURNAL OF CLINICAL INVESTIGATION

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

(2009) W M Liu et al.   BRITISH JOURNAL OF CANCER

Epidemiology of biliary tract cancers: an update

(2008) G. Randi et al.   ANNALS OF ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Systemic Therapy for Biliary Tract Cancers

(2008) A. F. Hezel et al.   ONCOLOGIST